Business
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company
About this update from Candel Therapeutics, Inc.
[{"type":"text","content":"NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update. “In the first quarter, we continued to advance our off-the-shelf investigational viral immunotherapies designed to produce an individualized cancer response, both of which have shown early clinical promise,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. “We are well positioned to announce important catalysts throughout the year. In the near-term, we will present new data from our CAN-3110 glioma clinical trial at ASGCT and we will provide an overview of our non-small cell lung cancer clinical trial design, study protocol, and dosing regimen at ASCO. In addition, we remain on track to announce data from our phase 2 non-small cell lung and pancreatic cancer clinical trials in the second half of the year. We remain steadfast in our mission to improve survival while maintaining quality of life for patients living with cancer.” First Quarter 2023 & Recent Highlights Program Updates: CAN-2409 – Non-Small Cell Lung Cancer (NSCLC) In April, the U.S. Food and Drug Administration (FDA) granted fast track designation to CAN-2409 with valacyclovir in combination with pembrolizumab in order to improve survival or delay progression in patients with stage III/IV NSCLC who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy.Charu Aggarwal, MD, MPH, Associate Professor for Lung Cancer Excellence of the Perelman School of Medicine at University of Pennsylvania and Candel’s co-principal investigator, will present a trials-in-progress poster from the phase 2 NSCLC clinical trial at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4 in Chicago.The Company recently added a new cohort to its phase 2 NSCLC clinical trial which will evaluate three injections of CAN-2409.The Company plans to present additional data from its phase 2 NSCLC clinical trial in Q3 2023. CAN-2409 – Prostate Cancer The Company’s placebo-controlled...